Scientists from St. Petersburg Pasteur Institute have published a review lecture on hepatitis D, one of the most severe yet underestimated viral liver diseases. The article was published in the journal "HIV Infection and Immunosuppression."
This is not just a rare infection. Hepatitis D develops only in those already infected with the hepatitis B virus, but it significantly accelerates disease progression: cirrhosis and hepatocellular carcinoma develop significantly faster, and treatment remains a complex clinical challenge. Until recently, therapy was limited primarily to interferons, but the first targeted drugs are now becoming available, and the lecture's authors examine their capabilities and limitations in detail.
The work places particular emphasis on diagnostics. In Russia, there is no official registration of hepatitis D, but in some regions, such as Tyva and Yakutia, the proportion of infected hepatitis B carriers reaches 35%. However, many cases remain undetected due to low awareness and imperfect testing systems.
The authors emphasize that effective control of hepatitis D is only possible through a combination of three factors: expanded screening, the development of new treatment regimens, and, of course, widespread hepatitis B vaccination, without which the delta-N virus itself is capable of reproducing. The lecture not only summarizes accumulated knowledge but also sets a direction for further research, which is especially important in the context of a changing epidemiological picture and global migration.